ISCO Stock — International Stem Cell Corp

International Stem Cell Corp (ISCO)

Updated October 16, 2026.

ISCO is a Stock. Its deepest 1-year drawdown was 50.4%.

International Stem Cell Corporation is a clinical-stage biotechnology company developing neural stem cell therapies for neurological diseases including Parkinson's disease, stroke, and Alzheimer's disease, while also commercializing anti-aging skincare products and human cell culture products for research applications across multiple disease areas. The company does not currently have an established distribution schedule. This stock may appeal to investors seeking exposure to early-stage biotechnology development with potential long-term therapeutic applications.

ISCO performance

Returns are updating. ISCO's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 50.4%.

ISCO key facts

Asset type

Stock

Asset class

Equity

Inception date

01/08/2007

Distribution frequency

None

Last close

$0.29 (as of 2026-10-16)

Market cap

$2,321,273

Average volume

6000.0

Beta

-0.039

Payout ratio

0.0%

EPS

$-0.08

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ISCO risks and drawbacks

The deepest 1-year drawdown on record here is 50.4%.

Who may consider ISCO — and who may not

It is a weaker fit for investors who need monthly cash flow (ISCO does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on ISCO

• All tickers starting with I

Tagged: Healthcare.

Frequently asked questions